Aethlon Medical Completes Pre-Funded Warrant Exercises, Simplifying Equity
TipRanks (Tue, 17-Mar 9:52 AM ET)
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
Globe Newswire (Fri, 13-Mar 8:35 AM ET)
Aethlon Medical Engages Maxim Group LLC to Evaluate Strategic Opportunities
PRNewswire (Thu, 12-Mar 8:01 AM ET)
Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th
Globe Newswire (Tue, 10-Mar 10:21 AM ET)
Aethlon Medical to Present at the Life Sciences Investor Forum on March 12th
Globe Newswire (Fri, 6-Mar 8:35 AM ET)
Presenting on Emerging Growth Conference 90 Day 2 on February 26; Register to live stream
Globe Newswire (Wed, 25-Feb 7:00 AM ET)
Presenting on Emerging Growth Conference 90 Day 1 on February 25; Register to live stream
Globe Newswire (Tue, 24-Feb 7:00 AM ET)
Aethlon Medical to Present on the Emerging Growth Conference on February 25th 2026
PRNewswire (Mon, 23-Feb 8:01 AM ET)
Aethlon Medical Announces Fiscal Q3 2026 Financial Results and Corporate Update
PRNewswire (Thu, 12-Feb 4:15 PM ET)
PRNewswire (Wed, 4-Feb 8:01 AM ET)
Aethlon Medical Inc is a medical therapeutic company. The company is focused on addressing unmet needs in health and biodefense. The company is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and eliminate life-threatening viruses from the circulatory system.
Aethlon Medical trades on the NASDAQ stock market under the symbol AEMD.
As of March 19, 2026, AEMD stock price declined to $2.21 with 12,842 million shares trading.
AEMD has a beta of 1.19, meaning it tends to be more sensitive to market movements. AEMD has a correlation of 0.02 to the broad based SPY ETF.
AEMD has a market cap of $2.91 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, AEMD traded as high as $576.00 and as low as $1.36.
AEMD has underperformed the market in the last year with a return of -92.9%, while the SPY ETF gained +18.9%. In the last 3 month period, AEMD fell short of the market, returning -21.9%, while SPY returned -1.9%. However, in the most recent 2 weeks AEMD has outperformed the stock market by returning +20.8%, while SPY returned -3.7%.
AEMD support price is $2.09 and resistance is $2.39 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AEMD shares will trade within this expected range on the day.